甲状腺间变性癌
医学
甲状腺癌
癌症研究
甲状腺
癌症
放射治疗
内科学
作者
Srihari Uppalapati,Lahanya Guha,Hemant Kumar,Amit Mandoli
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2024-03-01
卷期号:24 (3): 245-270
被引量:2
标识
DOI:10.2174/1568009623666230707155145
摘要
Anaplastic thyroid cancer is the rarest, most aggressive, and undifferentiated class of thyroid cancer, accounting for nearly forty percent of all thyroid cancer-related deaths. It is caused by alterations in many cellular pathways like MAPK, PI3K/AKT/mTOR, ALK, Wnt activation, and TP53 inactivation. Although many treatment strategies, such as radiation therapy and chemotherapy, have been proposed to treat anaplastic thyroid carcinoma, they are usually accompanied by concerns such as resistance, which may lead to the lethality of the patient. The emerging nanotechnology-based approaches cater the purposes such as targeted drug delivery and modulation in drug release patterns based on internal or external stimuli, leading to an increase in drug concentration at the site of the action that gives the required therapeutic action as well as modulation in diagnostic intervention with the help of dye property materials. Nanotechnological platforms like liposomes, micelles, dendrimers, exosomes, and various nanoparticles are available and are of high research interest for therapeutic intervention in anaplastic thyroid cancer. The pro gression of the disease can also be traced by using magnetic probes or radio-labeled probes and quantum dots that serve as a diagnostic intervention in anaplastic thyroid cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI